• #LGM Pharma is a Olopatadine Hydrochloride CAS# 140462-76-6 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 140462-76-6
  • AHFC code: 04:00.0
  • Synonyms: 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid, hydrochloride, Allelock, ALO 4943A, ALO4943A, DE 114, Dibenz(b,e)oxepin-2-acetic acid, 11-(3-(dimethylamino)propylidene)-6,11-dihydro-, hydrochloride, (Z)-, KW 4679, KW4679, Olopatadine HCl, Olopatadine hydrochloride, Olopax, Olopine, Pataday, Patadine, Patanase, Patanol, Pazeo, UNII-2XG66W44KF
  • ATC Code: R01AC08" S01GX09
  • Chemical Formula: C21-H23-N-O3.Cl-H
  • Molecular Weight: 373.8785
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00768
  • SMILES: c12C(c3c(cccc3)COc1ccc(c2)CC(O)=O)=C/CCN(C)C.Cl
  • InChl: 1S/C21H23NO3.ClH/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24;/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24);1H/b18-8-;
  • PubChem: 5281071
  • IUPAC: 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid hydrochloride Dibenz(b,e)oxepin-2-acetic acid, 11-(3-dimethylamino)propylidene)-6,11-dihydro-, hydrochloride, (Z)-

Additional Details

Indication:
Pharmacodynamics:
Mode of Action:
Metabolism:
Toxicity:
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials